Tissue Inhibitor of Metalloproteinase-2 Polymorphisms and Risk for HIV-Associated Neurocognitive Disorder

Table 8

Multivariate analysis between patients with and without HAND.

Variables	B	S.E.	df	value	OR (95% CI)
-418GG			2	0.67
-418GC	0.357	0.460	1	0.43	1.42 (0.58-3.52)
-418CC	-0.189	0.66	1	0.77	0.82 (0.22-3.05)
303GG			2	0.04
303GA	0.60	0.43	1	0.16	1.83 (0.78-4.29)
303AA	3.36	1.48	1	0.02	28.98 (1.59-527-23)
			2	0.001
Intermediate disease stage (CD4 201-350)	1.895	0.525	1	<0.001	6.65 (2.37-18.63)
Advanced disease stage (CD4 <200)	0.857	0.473	1	0.07	2.35 (2.35-5.95)
Age	0.048	0.030	1	0.10	1.05 (0.99-1.11)
Sex	0.861	0.429	1	0.04	2.36 (1.02-5.47)
Tobacco user	1.296	0.637	1	0.42	3.65 (1.04-12.73)
Alcohol user	-1.038	.634	1	0.10	0.35 (0.10-1.22)

TIMP-2 -418G/C and 303G/A polymorphism; age 18-50 years, sex, tobacco user, alcohol user, baseline CD4. Significant values (<0.05) represented and related OR (95% CI) have been shown in bold.